SCHEMBL2239196

SCHEMBL2239196

COC[C@@](OC(=O)O)(C(=O)NCc1ccccc1)C(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.51
MMP8 P22894 4/20 0.47
OPRK1 P41145 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 1/20 0.45
GLA P06280 1/20 0.45
HPGD P15428 1/20 0.45
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PPID Q08752 1/20 0.44
LMNA P02545 1/20 0.43
RAB9A P51151 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA3 P07451 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2239202 1.00 RIPK1 (0.51) RIPK1MMP8OPRK1SMN1; SMN2TP53
SCHEMBL2239194 0.92 RIPK1 (0.51) RIPK1MMP8OPRK1SMN1; SMN2TP53
SCHEMBL2356134 0.76 ALDH1A1 (0.34) MMP8SMN1; SMN2L3MBTL1CA12CA1
SCHEMBL1737445 0.74 RIPK1 (0.49) RIPK1MMP8OPRK1SMN1; SMN2TP53
SCHEMBL2749492 0.73 RIPK1 (0.63) RIPK1MMP8OPRK1SMN1; SMN2TP53
SCHEMBL1516186 0.72 RIPK1 (0.71) RIPK1MMP8OPRK1SMN1; SMN2LMNA
SCHEMBL21011243 0.72 RIPK1 (0.50) RIPK1MMP8OPRK1SMN1; SMN2TP53
SCHEMBL16644093 0.71 RIPK1 (0.69) RIPK1MMP8OPRK1SMN1; SMN2MAPT
SCHEMBL432436 0.71 RIPK1 (0.69) RIPK1MMP8OPRK1SMN1; SMN2MAPT
SCHEMBL5544358 0.70 OPRK1 (0.66) RIPK1MMP8OPRK1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES PRIVATE LIMITED (IN) 2013-02-14 US claimed
EP-2534127-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN Laboratories Limited (IN) 2012-12-19 EP claimed
WO-2011099033-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES LIMITED (IN) 2011-08-18 WO claimed
US-8907132-B2 Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide MSN LABORATORIES PRIVATE LIMITED (IN) 2014-12-09 US disclosed
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES PRIVATE LIMITED (IN) 2013-02-14 US disclosed
EP-2534127-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN Laboratories Limited (IN) 2012-12-19 EP disclosed
WO-2011099033-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES LIMITED (IN) 2011-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE AMY1A, PTMA, NAAA RIPK1 4808/4885MMP8 4364/4885OPRK1 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.